Clopidogrel in non-ST-segment elevation acute coronary syndromes

European Heart Journal, Supplement

Volumn 8, Issue G, 2006, Pages

  Mehta, Shamir R ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Aspirin; Clopidogrel; Coronary disease; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; APROTININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DRUG DOSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG LOADING DOSE; DRUG SAFETY; HEART INFARCTION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE;

EID: 33749529961     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul051     Document Type: Review

References (27)

1. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelets adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature 1979;279:636-638.
2. Fox JE. The platelet cytoskeleton. Thromb Haemost 1993;70: 884-893.
3. Hoylaerts MF. Amplification loops: release reaction. In: Gresele P, Page C, Fuster V, Vermylen J, ed. Platelets in Thrombotic and Non-thrombotic Disorders. Cambridge, UK: Cambridge Univesity Press; 2002.
4. Calvete JJ, Mann K, Schafer W et al. Proteolytic of the RGD-binding and non RGD-binding conformers of platelet integrin GP IIb/IIIa. Clues for identification of regions involved in receptor's activation. Biochem J 1994;298:1-7.
5. Lewis HD, Davis J, Archibald D et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983;309:396-403.
6. Cairns J, Gent M, Singer J et al. Aspirin, sulphinpyrazone, or both in unstable angina. N Engl J Med 1985;313:1369-1375.
7. Theroux P, Ouimet H, McCans J et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988;319:1105-1111.
8. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
10. The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 2001;345:494-502.
11. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107: 966-972.
12. Budaj A, Yusuf S, Mehta SR et al. for the CURE Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Insights from the CURE trial. Circulation 2002;106:1622-1626.
13. Fox KA, Mehta SR, Peters R et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-segment elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial. Circulation 2004;110:1202-1208.
14. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
15. Lewis BS, Mehta SR, Fox KAA et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J 2005;150:1177-1184.
16. Van der Liden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112(Suppl. 9):1276-1280.
17. Peters RJ, Mehta SR, Fox KA. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the CURE study. Circulation 2003;108:1682-1687.
18. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine versus selective invasive strategiesin patiens with acute coronary syndromes: A collaborative meta-analysis of the randomized trials. JAMA 2005;293:2908-2917.
19. Savcic M, Hauert J, Bachmann F et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25:15-19.
20. Bertrand ME, Rupprecht HJ, Urban P et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol 2004;16:325-329.
22. Lepantalo A, Virtanen KS, Heikkila J et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004;25:476-483.
23. Hochholzer W, Trenk D, Fundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-2564.
24. Montalescot G, Sideris G, Meuleman G. A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes. The ALBION trial. J Am Coll Cardiol 2006;48:931-938.
25. Kastrati A, Mehilli J, Schuhlen H et al. A clinical trial of elective PCI after pretreatment with clopiodgrel. N Engl J Med 2004; 350:232-238.
26. Mehilli J, Kastrati A, Schuhlen H et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective PCI after treatment with a high clopidogrel loading dose. Circulation 2004;110:3627-3635.
27. Patti G, Colonna G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005;111:2099-2106.